KR102913965B1 - 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체 - Google Patents

비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체

Info

Publication number
KR102913965B1
KR102913965B1 KR1020217007729A KR20217007729A KR102913965B1 KR 102913965 B1 KR102913965 B1 KR 102913965B1 KR 1020217007729 A KR1020217007729 A KR 1020217007729A KR 20217007729 A KR20217007729 A KR 20217007729A KR 102913965 B1 KR102913965 B1 KR 102913965B1
Authority
KR
South Korea
Prior art keywords
paclitaxel
treatment
prodrug
pharmaceutical composition
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217007729A
Other languages
English (en)
Korean (ko)
Other versions
KR20210083249A (ko
Inventor
조르지오 모스코니
다니엘라 자베스
카를로 피조카로
Original Assignee
피디아 파마슈티치 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피디아 파마슈티치 에스.피.에이. filed Critical 피디아 파마슈티치 에스.피.에이.
Publication of KR20210083249A publication Critical patent/KR20210083249A/ko
Application granted granted Critical
Publication of KR102913965B1 publication Critical patent/KR102913965B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217007729A 2018-10-25 2019-10-23 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체 Active KR102913965B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000009731 2018-10-25
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
PCT/IB2019/059073 WO2020084525A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer

Publications (2)

Publication Number Publication Date
KR20210083249A KR20210083249A (ko) 2021-07-06
KR102913965B1 true KR102913965B1 (ko) 2026-01-16

Family

ID=65324453

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007729A Active KR102913965B1 (ko) 2018-10-25 2019-10-23 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체

Country Status (21)

Country Link
US (4) US20200397909A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870233B1 (cg-RX-API-DMAC7.html)
JP (1) JP7518815B2 (cg-RX-API-DMAC7.html)
KR (1) KR102913965B1 (cg-RX-API-DMAC7.html)
CN (2) CN119792555A (cg-RX-API-DMAC7.html)
CA (1) CA3112188A1 (cg-RX-API-DMAC7.html)
DK (1) DK3870233T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190614A1 (cg-RX-API-DMAC7.html)
ES (1) ES2971217T3 (cg-RX-API-DMAC7.html)
FI (1) FI3870233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240188T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066288T2 (cg-RX-API-DMAC7.html)
IT (1) IT201800009731A1 (cg-RX-API-DMAC7.html)
LT (1) LT3870233T (cg-RX-API-DMAC7.html)
MA (1) MA63879B1 (cg-RX-API-DMAC7.html)
PL (1) PL3870233T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870233T (cg-RX-API-DMAC7.html)
RS (1) RS65193B1 (cg-RX-API-DMAC7.html)
SI (1) SI3870233T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400021T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020084525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000007747A1 (it) 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035629A2 (en) 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH666897A5 (fr) 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
IT1263393B (it) 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis
IT1402384B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium
EP3760707B1 (en) 2011-11-09 2025-11-19 Fibrobiologics, Inc. Fibroblasts for use in the treatment of degenerative disc disease
IT201600079633A1 (it) 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico
CN110859962B (zh) 2019-11-25 2021-01-22 山东大学 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035629A2 (en) 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Urology, 2011, 185, 445-449.
Urologic oncology: Seminars and original investigations, 2013, 31, 1261-1269.

Also Published As

Publication number Publication date
PL3870233T3 (pl) 2024-05-06
US20210196833A1 (en) 2021-07-01
EP3870233B1 (en) 2023-12-06
KR20210083249A (ko) 2021-07-06
DK3870233T3 (da) 2024-02-05
US12465649B2 (en) 2025-11-11
CA3112188A1 (en) 2020-04-30
US20210268119A1 (en) 2021-09-02
CN119792555A (zh) 2025-04-11
FI3870233T3 (fi) 2024-02-07
JP2022503771A (ja) 2022-01-12
EA202190614A1 (ru) 2021-06-03
HRP20240188T1 (hr) 2024-05-10
HUE066288T2 (hu) 2024-07-28
RS65193B1 (sr) 2024-03-29
CN112805035A (zh) 2021-05-14
ES2971217T3 (es) 2024-06-04
US20240123077A1 (en) 2024-04-18
SI3870233T1 (sl) 2024-03-29
US20200397909A1 (en) 2020-12-24
MA63879B1 (fr) 2024-02-29
EP3870233A1 (en) 2021-09-01
SMT202400021T1 (it) 2024-03-13
IT201800009731A1 (it) 2020-04-25
LT3870233T (lt) 2024-02-26
JP7518815B2 (ja) 2024-07-18
WO2020084525A1 (en) 2020-04-30
PT3870233T (pt) 2024-02-01

Similar Documents

Publication Publication Date Title
Wang et al. Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies
JP4704753B2 (ja) ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類
CN107669632B (zh) 药物载体、胶束、药物制剂、及其制备方法和用途
US20240123077A1 (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
WO2010106169A1 (en) Optical imaging agents
CN115667214A (zh) 包括药物二聚体的纳米颗粒及其用途
US20200276183A1 (en) Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
WO2019210414A1 (en) Fucan-based compounds and complexes
Sun et al. Polysaccharide hydrogels regulate macrophage polarization and enhance the anti-tumor efficacy of melanoma
US9962469B2 (en) Adhesion-preventing preparation comprising composition comprising polycationic triblock copolymer and polyanionic polymer
Lian et al. Rational design of hybrid nanomicelles integrating mucosal penetration and P-glycoprotein inhibition for efficient oral delivery of paclitaxel
US20250345457A1 (en) Functionalized diblock copolymer and its preparation method and application
KR102162774B1 (ko) 커큐민 유도체 함유 pH 민감성 블록 공중합체를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물
KR101554703B1 (ko) 벤조일옥시신남알데히드-폴리에틸렌글리콜 결합 마이셀에 아연 프로토포르피린을 담지한 pH 감응형 항암 전구약물 및 이의 제조방법
EP2489351A1 (en) Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof
HK40048954B (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
HK40048954A (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
CN112142986A (zh) 一种官能化双嵌段共聚物及其制备方法和用途
EA043782B1 (ru) Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря
US20210154322A1 (en) Refillable drug delivery by affinity homing
JPWO2005037292A1 (ja) 糖鎖含有キトサン誘導体を含有する内視鏡手術用粘膜下膨隆液組成物
Zhu Nanoparticles Targeting Tumour Associated Macrophages
Hou et al. Tumor Microenvironment-Responsive Ternary Nanosystem for Enhanced Antitumor and Antimetastasis Efficacy Against Breast Cancer
CN121891549A (zh) 一种基于紫杉醇衍生物的组合物及其制备方法和应用
WO2022063209A1 (zh) 一种官能化双嵌段共聚物及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 33